The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles； the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen； therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen； and related pharmaceutical compositions and packages thereof.本發明係關於治療或預防有需要之患者之增殖性疾病之方法，其係藉由經口投與治療有效量之式(I)之α-同型異構體選擇性磷脂醯肌醇3-激酶抑制劑化合物或其醫藥上可接受之鹽至少兩個連續5天週期來達成，其中在該等連續5天週期之間約兩天至約三天之時段內並不向該患者投與該化合物；該式(I)化合物或其醫藥上可接受之鹽用以製造根據該劑量療法投與之用於治療或預防增殖性疾病之醫藥之用途；包括根據該劑量療法投與該式(I)化合物或其醫藥上可接受之鹽之治療性療法；及其相關醫藥組合物及包裝。
